Vicapsys Life Sciences, Inc.

VICPdata completeness 75%5 fiscal years on file

Data notes: no data for concept 'revenue'; no data for concept 'capex'; no data for concept 'incomeTaxExpense'

The thesis, from the filings

Vicapsys Life Sciences, Inc. earns about -467% on equity, but has diluted owners by 98% over 5 years — worth asking whether the growth reaches owners. The cash-flow models don't apply cleanly here — the ledger says why below.Whether it’s worth owning at today’s price is the last question — and yours to answer, below.

i. The business — what you’d actually own

Figure	FY 2019	FY 2020	FY 2021	FY 2022	FY 2023
Revenue	—	—	—	—	—
Net income	−$1.41M¹	−$765,844²	−$236,871³	−$984,790⁴	−$1.18M⁴
Operating cash flow	−$970,264⁵	−$262,897⁶	−$443,974⁷	−$238,197⁸	−$417,524⁸
Capital expenditure	—	—	—	—	—
Free cash flow (derived)	—	—	—	—	—
Total debt	—	—	—	—	$18,712⁹
Cash & equivalents	$264,166¹⁰	$1,269¹¹	$217,295¹²	$14,097¹³	$9,422¹³
Diluted shares	17.5M	17.5M	17.7M	30.6M	34.5M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

ii. Your slice — ownership made literal

If you owned

Net assets behind them

−$0.56

your share of equity

Profit it earned you last year

−$0.34

Free cash flow it threw off

—

Debt you’d be carrying

$0.01

10 shares is a claim on −$0.56 of net worth that earned you −$0.34 last year, against $0.01 of debt.

iii. Is this a good business?

Moat signal · return on equity

-467% avg · 5y

FY19 -467%FY20 —FY21 —FY22 —FY23 —

It earned an average -467% on equity over 5 years. Compare that to what it costs to fund the business.

seeing a moat in the numbers →

Management signal · capital allocation

+98% shares · 5y

Share count is up 98% over 5 years — owners have been diluted. Worth asking what they got for it. Total debt has held roughly steady.

reading capital allocation →

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.1.0

DCF · Growth Exit 10Y

not applicable

only 0 years of FCF (need ≥3) — model not applicable

DCF · Growth Exit 5Y

not applicable

only 0 years of FCF (need ≥3) — model not applicable

Earnings Power Value

not applicable

normalized (5y-median) earnings non-positive — EPV undefined

Graham Number

not applicable

diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Sources — the receipts

10-K · period ending 2019-12-31 · accession 0001493152-21-022984 (NetIncomeLoss)
10-K · period ending 2020-12-31 · accession 0001493152-22-006994 (NetIncomeLoss)
10-K · period ending 2021-12-31 · accession 0001493152-23-012267 (NetIncomeLoss)
10-K · period ending 2022-12-31 · accession 0001493152-24-041809 (NetIncomeLoss)
10-K · period ending 2019-12-31 · accession 0001493152-21-022984 (NetCashProvidedByUsedInOperatingActivities)
10-K · period ending 2020-12-31 · accession 0001493152-22-006994 (NetCashProvidedByUsedInOperatingActivities)
10-K · period ending 2021-12-31 · accession 0001493152-23-012267 (NetCashProvidedByUsedInOperatingActivities)
10-K · period ending 2022-12-31 · accession 0001493152-24-041809 (NetCashProvidedByUsedInOperatingActivities)
10-K · period ending 2023-12-31 · accession 0001493152-24-041809 (ShortTermBorrowings)
10-K · period ending 2019-12-31 · accession 0001493152-21-022984 (CashAndCashEquivalentsAtCarryingValue)
10-K · period ending 2020-12-31 · accession 0001493152-22-006994 (CashAndCashEquivalentsAtCarryingValue)
10-K · period ending 2021-12-31 · accession 0001493152-23-012267 (CashAndCashEquivalentsAtCarryingValue)
10-K · period ending 2022-12-31 · accession 0001493152-24-041809 (CashAndCashEquivalentsAtCarryingValue)